1. Home
  2. SNDX vs ANDE Comparison

SNDX vs ANDE Comparison

Compare SNDX & ANDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • ANDE
  • Stock Information
  • Founded
  • SNDX 2005
  • ANDE 1947
  • Country
  • SNDX United States
  • ANDE United States
  • Employees
  • SNDX N/A
  • ANDE N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • ANDE Farming/Seeds/Milling
  • Sector
  • SNDX Health Care
  • ANDE Industrials
  • Exchange
  • SNDX Nasdaq
  • ANDE Nasdaq
  • Market Cap
  • SNDX 1.1B
  • ANDE 1.3B
  • IPO Year
  • SNDX 2016
  • ANDE N/A
  • Fundamental
  • Price
  • SNDX $16.24
  • ANDE $40.95
  • Analyst Decision
  • SNDX Strong Buy
  • ANDE Buy
  • Analyst Count
  • SNDX 10
  • ANDE 3
  • Target Price
  • SNDX $37.50
  • ANDE $51.67
  • AVG Volume (30 Days)
  • SNDX 2.9M
  • ANDE 345.2K
  • Earning Date
  • SNDX 08-04-2025
  • ANDE 08-04-2025
  • Dividend Yield
  • SNDX N/A
  • ANDE 2.03%
  • EPS Growth
  • SNDX N/A
  • ANDE N/A
  • EPS
  • SNDX N/A
  • ANDE 2.35
  • Revenue
  • SNDX $77,933,000.00
  • ANDE $11,539,093,000.00
  • Revenue This Year
  • SNDX $434.67
  • ANDE $9.10
  • Revenue Next Year
  • SNDX $108.62
  • ANDE $2.78
  • P/E Ratio
  • SNDX N/A
  • ANDE $16.38
  • Revenue Growth
  • SNDX 2126.66
  • ANDE N/A
  • 52 Week Low
  • SNDX $8.58
  • ANDE $31.03
  • 52 Week High
  • SNDX $22.50
  • ANDE $51.58
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 79.83
  • ANDE 67.77
  • Support Level
  • SNDX $15.36
  • ANDE $37.91
  • Resistance Level
  • SNDX $16.33
  • ANDE $38.79
  • Average True Range (ATR)
  • SNDX 0.78
  • ANDE 1.52
  • MACD
  • SNDX 0.31
  • ANDE 0.24
  • Stochastic Oscillator
  • SNDX 96.87
  • ANDE 99.02

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

Share on Social Networks: